Kidney Transplant – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Kidney Transplant Market Outlook
Thelansis’s “Kidney Transplant Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Kidney Transplant treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Kidney
Transplant Overview
A kidney
transplant is a surgical procedure in which a healthy kidney from either a
living or deceased donor is placed into the lower abdomen. Transplantation is
the kidney replacement therapy for suitable patients with end-stage kidney
disease (ESKD). In 2020, a record 25,500 kidney transplants were performed in
the US. Approximately 72% of these transplants were completed on deceased
donors. Transplant recipients were 61% men, and half had diabetes mellitus
(30.1%) or hypertension (20.0%) as the listed cause of ESKD, with
glomerulonephritis (17.5%) and cystic renal disease (12.8%) being less common.
The average kidney transplant will cost $450,000 in 2020.
Charges for transplant admission, including surgery, are the most expensive
line item, accounting for 34% of total costs. Despite rising medication costs,
immunosuppression and other transplant-related drugs such as prophylactic
antibiotics account for only 7% of total charges (from transplant to 6 months
post-transplant).
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment